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Studies with nitric oxide (NO) inhalation suggest trans-
formation of NO in the lung into a more long-lived bioactive
NO species that also has distal effects [1,2]. The exact
nature of these species has not been pinpointed, but
probable candidates include circulating nitrite anions and/or
S-nitrosothiols [3]. When using inhaled NO therapeutically for
pulmonary disorders, the dose is typically expressed as the
concentration of NO without adjustments for body size.
When inhaling 10 ppm NO, the concentration of NO that
reaches the lungs with every breath is the same whether it in
a mouse, a premature infant or an adult. The minute
ventilation in relation to body weight, however, is about three
to four times higher in a premature infant compared with an
adult, so the resulting accumulation of bioactive NO
metabolites in blood is much greater. This greater
accumulation suggests that the dose of inhaled NO should
be adjusted in relation to body weight, and also calls for
some caution when extrapolating results from animal data to
humans. A concentration of inhaled NO that is effective in a
small animal may therefore not be sufficient in humans.
Conversely, a concentration that is effective and safe in
adults may cause unwanted toxic effects in premature infants.
Several factors will affect the metabolism of inhaled NO into
bioactive circulating NO species. The vast majority of inhaled
NO eventually ends up as nitrate, which is considered
biologically inert. In awake subjects, however, nitrate under-
goes enterosalivary circulation and is reduced to nitrite in the
oral cavity [4]. Swallowed nitrite then reenters the circulation,
where it can be further reduced to bioactive NO [5]. In
intubated sedated patients the enterosalivary nitrate/nitrite
cycle is disrupted, and consequently less nitrite is generated.
The levels of circulating NO species will also depend on NO
oxidation in blood into nitrite, on renal excretion and on the
activity of the reductive systems that ultimately catalyse NO
formation from the circulating NO metabolites [3].
In summary, it is clear that inhaled NO has distal effects
outside the lungs that may be harnessed therapeutically in
the future; for example, in the prevention of ischemia-
reperfusion injury. Although the precise nature of the NO
metabolite(s) responsible for these effects remains to be
pinpointed, there are indications that the nitrite anion plays an
active role. In experimental settings and in future clinical trials
we should consider adjusting the dose of inhaled NO in
relation to body size and should consider other factors that
may affect the transduction of NO bioactivity to the target
organ. Finally, the possibility of delivering the active NO
metabolites directly instead of via NO inhalation should also
be considered.
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